Currently Director, Competitive Intelligence, within the Business Development & Licensing team of BioInvent, a leading Swedish clinical-stage Oncology company. The key focus is managing and developing insights, market research, strategic initiatives, and partnering, with innovative blueprints. Additionally, establish and foster a cross-functional data-driven portfolio strategy for C-level leadership and senior stakeholders. Possess a Doctorate in Medicine (Oncology) with 10+ years of global experience working at organizations such as AstraZeneca (US), Harvard Medical School (US) and Sahlgrenska Academy (Sweden), publishing 25+ articles and conference proceedings internationally.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.